Gsa Capital Partners LLP Theravance Biopharma, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 162,987 shares of TBPH stock, worth $1.52 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
162,987
Previous 229,780
29.07%
Holding current value
$1.52 Million
Previous $1.85 Million
17.17%
% of portfolio
0.11%
Previous 0.14%
Shares
14 transactions
Others Institutions Holding TBPH
# of Institutions
129Shares Held
46.5MCall Options Held
600Put Options Held
300-
Madison Avenue Partners, LP New York, NY9.51MShares$88.9 Million14.29% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$69.7 Million2.02% of portfolio
-
Newtyn Management, LLC New York, NY4.76MShares$44.5 Million9.1% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$35.3 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$25.8 Million2.79% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $624M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...